MedPath

江苏长江药业有限公司

Ownership
-
Established
2002-06-20
Employees
-
Market Cap
-
Website
http://www.jscjyy.cn

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

105

NMPA:105

Drug Approvals

Lidocaine Hydrochloride Injection

Product Name
盐酸利多卡因注射液
Approval Number
国药准字H20253207
Approval Date
Jan 14, 2025
NMPA

Levofloxacin and Sodium Chloride Injection

Product Name
左氧氟沙星氯化钠注射液
Approval Number
国药准字H20244645
Approval Date
Aug 5, 2024
NMPA

Ciprofloxacin Lactate and Sodium Chloride Injection

Product Name
乳酸环丙沙星氯化钠注射液
Approval Number
国药准字H20244007
Approval Date
Jun 11, 2024
NMPA

Moxifloxacin Hydrochloride and Sodium Chloride Injection

Product Name
盐酸莫西沙星氯化钠注射液
Approval Number
国药准字H20243494
Approval Date
Apr 17, 2024
NMPA

Azithromycin Capsules

Product Name
阿奇霉素胶囊
Approval Number
国药准字H20083611
Approval Date
Apr 17, 2023
NMPA

Spironolactone Tablets

Product Name
螺内酯片
Approval Number
国药准字H20084493
Approval Date
Apr 17, 2023
NMPA

Hydrotalcite Granules

Product Name
铝碳酸镁颗粒
Approval Number
国药准字H20183241
Approval Date
Apr 17, 2023
NMPA

Fleroxacin Capsules

Product Name
氟罗沙星胶囊
Approval Number
国药准字H20084500
Approval Date
Apr 16, 2023
NMPA

Ropivacaine Hydrochloride and Sodium Chloride Injection

Product Name
盐酸罗哌卡因氯化钠注射液
Approval Number
国药准字H20223742
Approval Date
Oct 11, 2022
NMPA

Ropivacaine Hydrochloride and Sodium Chloride Injection

Product Name
盐酸罗哌卡因氯化钠注射液
Approval Number
国药准字H20223743
Approval Date
Oct 11, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 11
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.